Aurinia Pharmaceuticals Inc. - Common Shares, no par value (AUPH) Institutional Ownership

13F Institutional Holders and Ownership History from Q3 2014 to Q4 2025

Type / Class
Equity / Common Shares, no par value
Symbol
AUPH on Nasdaq
Shares outstanding
130,702,820
Price per share
$14.57
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
71,954,650
Total reported value
$1,147,109,836
% of total 13F portfolios
0%
Share change
+4,824,228
Value change
+$82,925,826
Number of holders
252
Price from insider filings
$14.57
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Aurinia Pharmaceuticals Inc. - Common Shares, no par value (AUPH) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
TANG CAPITAL MANAGEMENT LLC 7.3% $81,238,950 10,029,500 TANG CAPITAL MANAGEMENT, LLC 28 Feb 2025
ILJIN SNT Co., Ltd. 5% $57,509,241 6,535,141 Chin Kyu Huh 11 Aug 2025
ARMISTICE CAPITAL, LLC 4.5% $51,840,000 6,400,000 Armistice Capital, LLC 31 Dec 2024

As of 31 Dec 2025, 252 institutional investors reported holding 71,954,650 shares of Aurinia Pharmaceuticals Inc. - Common Shares, no par value (AUPH). This represents 55% of the company’s total 130,702,820 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Aurinia Pharmaceuticals Inc. - Common Shares, no par value (AUPH) together control 41% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
TANG CAPITAL MANAGEMENT LLC 8.7% 11,329,500 0% 8.9% $180,705,525
BlackRock, Inc. 6.1% 7,928,129 +6.4% 0% $126,453,658
NEA Management Company, LLC 3% 3,969,834 0% 3.2% $63,318,852
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 2.6% 3,387,194 +0.39% 0.03% $54,025,744
STATE STREET CORP 1.9% 2,501,992 -7.1% 0% $39,906,772
MORGAN STANLEY 1.7% 2,216,915 +14% 0% $35,359,797
TWO SIGMA INVESTMENTS, LP 1.5% 1,962,742 +46% 0.05% $31,305,735
RENAISSANCE TECHNOLOGIES LLC 1.2% 1,590,135 +9.7% 0.04% $25,362,653
MARSHALL WACE, LLP 1.2% 1,574,957 +6.2% 0.02% $25,120,564
D. E. Shaw & Co., Inc. 1.2% 1,532,273 +68% 0.02% $24,439,755
GEODE CAPITAL MANAGEMENT, LLC 1.2% 1,507,869 +1.5% 0% $24,046,973
VANGUARD GROUP INC 1.1% 1,449,884 -6.9% 0% $23,125,650
TWO SIGMA ADVISERS, LP 1% 1,305,800 +172% 0.04% $20,827,510
KOTLER KEVIN 0.94% 1,224,846 0% 14% $19,536,294
NOMURA HOLDINGS INC 0.88% 1,156,133 +266% 0.14% $18,440,321
JACOBS LEVY EQUITY MANAGEMENT, INC 0.87% 1,139,249 -6.6% 0.07% $18,171,022
GOLDMAN SACHS GROUP INC 0.77% 1,006,333 +20% 0% $16,051,011
JANE STREET GROUP, LLC 0.7% 910,737 +34% 0.02% $14,526,255
JUPITER ASSET MANAGEMENT LTD 0.69% 899,483 +9.2% 0.11% $14,346,754
Qube Research & Technologies Ltd 0.67% 874,345 -24% 0.02% $13,945,803
Man Group plc 0.65% 852,671 +369% 0.03% $13,600,103
NORTHERN TRUST CORP 0.61% 800,144 -11% 0% $12,762,297
CITADEL ADVISORS LLC 0.6% 779,495 +11% 0.01% $12,432,945
VOLORIDGE INVESTMENT MANAGEMENT, LLC 0.57% 739,444 +44% 0.04% $11,794,132
MILLENNIUM MANAGEMENT LLC 0.56% 738,306 +634% 0.01% $11,775,981

Institutional Holders of Aurinia Pharmaceuticals Inc. - Common Shares, no par value (AUPH) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 71,954,650 $1,147,109,836 +$82,925,826 $15.95 252
2025 Q3 65,698,350 $726,012,410 +$84,257,823 $11.05 240
2025 Q2 58,318,900 $494,168,918 -$31,810,462 $8.47 216
2025 Q1 62,001,205 $498,579,335 +$33,892,897 $8.04 210
2024 Q4 57,799,592 $519,061,476 +$4,097,220 $8.98 197
2024 Q3 57,639,569 $422,207,215 +$21,955,759 $7.33 180
2024 Q2 55,307,620 $315,754,570 +$4,958,367 $5.71 168
2024 Q1 54,674,386 $273,920,542 +$3,860,760 $5.01 173
2023 Q4 53,220,649 $478,436,427 +$38,734,205 $8.99 186
2023 Q3 50,339,448 $391,141,750 -$739,167 $7.77 194
2023 Q2 49,820,766 $482,543,239 -$1,739,141 $9.68 197
2023 Q1 49,994,676 $547,934,449 +$7,051,204 $10.96 182
2022 Q4 51,117,260 $220,815,199 -$24,246,473 $4.32 181
2022 Q3 55,353,711 $416,255,629 +$28,431,118 $7.52 177
2022 Q2 50,117,033 $503,590,633 +$74,385,031 $10.05 191
2022 Q1 42,164,731 $521,893,499 +$1,302,371 $12.38 176
2021 Q4 38,512,517 $881,056,850 -$105,784,806 $22.87 180
2021 Q3 43,124,514 $954,392,864 -$114,507 $22.13 160
2021 Q2 49,010,949 $635,371,815 -$42,000,595 $12.96 162
2021 Q1 52,072,235 $676,156,911 -$80,619,096 $12.99 163
2020 Q4 57,920,959 $801,022,755 -$114,549,555 $13.83 139
2020 Q3 64,784,594 $954,040,391 +$75,038,433 $14.73 144
2020 Q2 58,637,850 $953,206,339 -$24,791,270 $16.25 127
2020 Q1 60,307,130 $875,021,915 +$158,173,274 $14.51 122
2019 Q4 48,880,484 $990,406,662 +$509,187,869 $20.26 110
2019 Q3 25,474,542 $136,035,080 -$23,251,716 $5.34 68
2019 Q2 29,347,880 $193,099,929 -$3,061,002 $6.58 71
2019 Q1 29,823,940 $193,853,541 +$49,275,242 $6.50 76
2018 Q4 22,212,575 $151,471,995 +$3,053,577 $6.82 59
2018 Q3 21,500,016 $144,548,400 +$1,928,619 $6.64 62
2018 Q2 21,282,120 $121,759,408 -$2,409,149 $5.63 65
2018 Q1 21,720,891 $112,732,308 -$10,024,771 $5.19 63
2017 Q4 23,825,802 $107,940,708 -$515,812 $4.53 66
2017 Q3 23,438,674 $146,961,556 +$2,094,667 $6.27 59
2017 Q2 23,175,243 $142,270,544 -$8,837,055 $6.13 64
2017 Q1 23,813,237 $174,794,651 +$114,421,765 $7.34 71
2016 Q4 8,627,972 $18,126,000 +$8,662,521 $2.10 22
2016 Q3 4,238,270 $12,814,000 -$8,129,564 $3.01 14
2016 Q2 7,070,693 $20,093,000 +$878,266 $2.78 13
2016 Q1 6,743,443 $19,673,000 +$25,044 $2.92 16
2015 Q4 6,732,938 $16,753,741 -$1,105,844 $2.47 14
2015 Q3 7,110,273 $20,112,000 -$538,914 $2.84 11
2015 Q2 7,222,335 $21,748,000 -$1,342,201 $3.02 13
2015 Q1 7,607,904 $33,247,000 -$3,826,120 $4.37 11
2014 Q4 8,484,410 $30,665,000 +$8,984,489 $3.61 9
2014 Q3 6,016,277 $19,267,000 +$19,267,000 $3.20 8